Table 3 Demographic characteristics: placebo-controlled studies
From: Suicidality and divalproex sodium: analysis of controlled studies in multiple indications
Characteristic | Treatment group | Total, N = 2,319, n (%) | P value | ||
|---|---|---|---|---|---|
| Â | Â | DVPX, N = 1,327, n (%) | Placebo, N = 992, n (%) | Â | Â |
Age, years | Mean ± SD | 44 ± 18 | 44 ± 19 |  |  |
| Â | Least-squares mean | 45 | 46 | Â | 0.7454a |
| Â | Range | 10 to 100 | 9 to 99 | Â | Â |
| Â | 5 to 17 | 15 (1) | 12 (1) | 27 (1) | 0.1413b |
| Â | 18 to 24 | 131 (10) | 83 (8) | 214 (9) | Â |
| Â | 25 to 30 | 140 (11) | 138 (14) | 278 (12) | Â |
| Â | 31 to 64 | 855 (64) | 617 (62) | 1,472 (63) | Â |
|  | ≥65 | 186 (14) | 142 (14) | 328 (14) |  |
Gender | Female | 740 (56) | 544 (55) | 1,284 (55) | 0.3087b |
| Â | Male | 587 (44) | 448 (45) | 1,035 (45) | Â |
Race | White Caucasian | 1,109 (84) | 825 (83) | 1,934 (83) | 0.4430b |
| Â | Other | 218 (16) | 167 (17) | 385 (17) | Â |
Participation duration, days | Mean ± SD | 68 ± 84 | 57 ± 64 |  | 0.2344a |
| Â | Least-squares mean | 60 | 57 | Â | Â |
| Â | Range | 1 to 400 | 1 to 391 | Â | Â |